drugset / Trial / NCT00343356

Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder

NCT00343356 ↗

Phase 2 Completed 138 enrolled LanZhou University
RandomizedParallel-groupOpen-labelPrevention

Summary

Biochemotherapy (combined immunotherapeutic drugs and chemotherapeutic drugs) has shown virtue than that use chemical or biological drugs alone in the treatment of some malignant tumor. Here we investigated the efficacy of sequential intravesical therapy with EPI and BCG to EPI or BCG alone in patients with transitional cell carcinoma of bladder cancer after surgical management.

Timeline

Start
1996-06
Primary completion
—
Completion
2003-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Trement Unknown — —